Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AugMMent: Tec-DRd vs DVRd in Newly Diagnosed Transplant-Eligible Multiple Myeloma
NCT07671287Phase 3Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Feb 2031
01
Overview
A Phase 3 trial of teclistamab in multiple myeloma (MM). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07671287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671287.